Ara
Toplam kayıt 17, listelenen: 1-10
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
(Sage Publications Ltd, 2018)
Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and ...
The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey Molecular Profiling in Advanced Cancers Trial (TUMPACT)
(Elsevier, 2020)
Background: Molecular genetic profiling (MGP) which has started to take an important part in cancer diagnosis and treatment in recent years, has entered the routineclinical practice much faster than expected. We aimed to ...
Outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical treatment
(Elsevier Science Inc, 2017)
...
Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors
(American Society of Clinical Oncology, 2016)
...
Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study
(American Society of Clinical Oncology, 2020)
...
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as first-tine treatment in HER2-negative advanced gastric cancer
(American Society of Clinical Oncology, 2014)
…
Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer
(Wiley, 2020)
What is known and objective Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. ...
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
(Springer, 2017)
Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active ...
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
(Springer, 2015)
Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...